JP2021526548A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021526548A5 JP2021526548A5 JP2021512351A JP2021512351A JP2021526548A5 JP 2021526548 A5 JP2021526548 A5 JP 2021526548A5 JP 2021512351 A JP2021512351 A JP 2021512351A JP 2021512351 A JP2021512351 A JP 2021512351A JP 2021526548 A5 JP2021526548 A5 JP 2021526548A5
- Authority
- JP
- Japan
- Prior art keywords
- mel
- dkla
- graph
- compare
- order
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
Claims (1)
- 前記疾患は、肺癌、転移癌、乳がんであることを特徴とする請求項11に記載の薬学的組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0051800 | 2018-05-04 | ||
KR20180051800 | 2018-05-04 | ||
PCT/KR2019/005438 WO2019212324A1 (ko) | 2018-05-04 | 2019-05-07 | 멜리틴-기반 세포사멸 유발 펩타이드로 m2 유사 종앙관련 대식세포의 표적화 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021526548A JP2021526548A (ja) | 2021-10-07 |
JP2021526548A5 true JP2021526548A5 (ja) | 2021-11-18 |
JP7234349B2 JP7234349B2 (ja) | 2023-03-07 |
Family
ID=68386643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021512351A Active JP7234349B2 (ja) | 2018-05-04 | 2019-05-07 | メリチンベースのアポトシース促進ペプチドペプチドでm2様腫瘍関連マクロファージの標的化 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11484601B2 (ja) |
EP (1) | EP3789041A4 (ja) |
JP (1) | JP7234349B2 (ja) |
KR (1) | KR102250412B1 (ja) |
CN (1) | CN112533640A (ja) |
AU (1) | AU2019264092B2 (ja) |
CA (1) | CA3099434C (ja) |
WO (1) | WO2019212324A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022109167A1 (en) * | 2020-11-20 | 2022-05-27 | The Johns Hopkins University | Membrane-active peptides and methods for reversible blood- brain barrier opening |
US20220354957A1 (en) * | 2021-05-07 | 2022-11-10 | Twinpig Biolab, Inc. | Peptides targeting macrophages, and conjugates, compositions, and uses thereof |
CN113336828B (zh) * | 2021-06-30 | 2022-03-25 | 中国海洋大学 | 抗菌肽yhx-3及其组合物和应用 |
CN114437193A (zh) * | 2022-01-29 | 2022-05-06 | 陕西未来多肽生物科技有限公司 | 一种金-蜂毒肽纳米杂化物及其应用 |
KR20230144960A (ko) * | 2022-04-07 | 2023-10-17 | 트윈피그바이오랩(주) | 신규 펩타이드 기반 면역항암제 |
WO2023204329A1 (ko) * | 2022-04-22 | 2023-10-26 | 트윈피그바이오랩(주) | 신규 펩타이드 기반 면역항암제 |
CN116589555B (zh) * | 2023-03-31 | 2024-02-06 | 广东医科大学 | 一种细胞穿梭肽及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5135736A (en) | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US5552391A (en) * | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
AUPQ014799A0 (en) * | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
DE602004009818T2 (de) * | 2003-11-05 | 2008-09-18 | Intercell Ag | Zusammensetzungen, die von melittin abgeleitet sind und peptide enthalten, und verfahren zur potenzierung von immunreaktionen gegen target-antigene |
WO2010063124A1 (en) * | 2008-12-05 | 2010-06-10 | Angiochem Inc. | Peptide therapeutic conjugates and uses thereof |
KR20110117788A (ko) | 2010-04-22 | 2011-10-28 | 대한민국(농촌진흥청장) | 멜리틴을 포함하는 섬유아세포-유사-활막세포의 활성을 억제하는 조성물 |
KR20110117789A (ko) | 2010-04-22 | 2011-10-28 | 대한민국(농촌진흥청장) | 멜리틴을 함유하는 동맥경화 치료용 조성물 |
KR101695792B1 (ko) * | 2014-09-04 | 2017-01-12 | 디오셀 주식회사 | 신규 세포막 투과 펩티드 및 생리활성 물질 전달체로서의 그의 용도 |
KR101935095B1 (ko) * | 2015-07-31 | 2019-01-04 | 이화여자대학교 산학협력단 | 신규한 세포투과성 펩타이드 |
CN106699896B (zh) * | 2016-12-05 | 2020-06-05 | 华中科技大学同济医学院附属协和医院 | 一种可自组装成水凝胶的肿瘤杀伤性多肽及其应用 |
KR102073273B1 (ko) | 2017-08-23 | 2020-03-02 | (주) 레느스랩 | 멜리틴을 포함하는 m2형 종양관련 대식세포 제거용 조성물 |
-
2019
- 2019-05-07 JP JP2021512351A patent/JP7234349B2/ja active Active
- 2019-05-07 AU AU2019264092A patent/AU2019264092B2/en active Active
- 2019-05-07 US US17/052,943 patent/US11484601B2/en active Active
- 2019-05-07 CA CA3099434A patent/CA3099434C/en active Active
- 2019-05-07 KR KR1020190053334A patent/KR102250412B1/ko active IP Right Grant
- 2019-05-07 CN CN201980030270.8A patent/CN112533640A/zh active Pending
- 2019-05-07 EP EP19796650.0A patent/EP3789041A4/en active Pending
- 2019-05-07 WO PCT/KR2019/005438 patent/WO2019212324A1/ko active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021526548A5 (ja) | ||
Obeid et al. | The role of tumor-associated macrophages in breast cancer progression | |
Rahman et al. | Chemopreventive potential of natural compounds in head and neck cancer | |
JP2023120393A5 (ja) | ||
Li et al. | β-Elemene against human lung cancer via up-regulation of P53 protein expression to promote the release of exosome. | |
Wu et al. | Dynamic education of macrophages in different areas of human tumors | |
JP2017530171A5 (ja) | ||
Kotlarz et al. | Differential interference of vitamin D analogs PRI-1906, PRI-2191, and PRI-2205 with the renewal of human colon cancer cells refractory to treatment with 5-fluorouracil | |
Fu et al. | Hirsutella sinensis inhibits lewis lung cancer via tumor microenvironment effector T cells in mice | |
Kiselev et al. | Preclinical antitumor activity of the diindolylmethane formulation in xenograft mouse model of prostate cancer | |
JP2015517471A5 (ja) | ||
Tian et al. | Systematic analysis of pemetrexed-based chemoradiotherapy for patients with locally advanced or metastatic esophageal cancer | |
Kubala | Modulation of cell proliferation and differentiation of human lung carcinoma cells by the interferon-alpha | |
Sakaguchi et al. | High-dose oral tegafur-uracil maintenance therapy in patients with uterine cervical cancer | |
Kapoor | Maspin and it’s evolving role in tumor progression in systemic malignancies | |
Huang et al. | Independent Adverse Prognosis of Elevated Serum LDH in Human Papillomavirus–Related Oropharyngeal Cancer | |
Hagiwara et al. | CD44V8-10 INVOLVES ACQUISITION OF CISPLATIN-RESISTANCE IN UROTHELIAL CANCER: MP83-10 | |
Jalalizadeh et al. | TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) POTENTIATES THE EFFECT OF BACILLUS CALMETTE-GUÉRIN (BCG) IN UROTHELIAL CARCINOMA MODEL: MP83-09 | |
Samejima et al. | P1. 05-018 Prognostic Impact of Tumor Shadow Disappearance Rate in Patients with Clinical IA Lung Adenocarcinoma | |
Ozdemir | Can a mast cell subtype (MCT) play a role in the progression of endometrial cancer through angiogenesis? | |
Brown et al. | An unusual presentation of metastatic disease: Cutaneous metastases from pulmonary adenocarcinoma manifesting as widespread plaques | |
Ferrarini | The Regulation of EU Financial Markets: Mifid 2 and Mifir | |
Ray-Coquard et al. | Paclitaxel–carboplatin with the oral IAP inhibitor Debio1143 in a subset of patients with recurrent epithelial ovarian cancer (EOC): Phase I | |
Buchanich et al. | Comparison of mortality rates between Appalachian coal mining counties with non-coal mining | |
Paulk et al. | C72 PREDICTIVE AND PROGNOSTIC MARKERS IN THORACIC ONCOLOGY: Histologic Grading Of Adenocarcinomas Of The Lung: Features Associated With Metastatic Potential And Survival |